Drug Eluting Contact Lenses

药物洗脱隐形眼镜

• 批准号: 7922001
• 负责人: Joseph B. Ciolino
• 金额: $ 21.28万
• 依托单位: MASSACHUSETTS EYE AND EAR INFIRMARY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7922001
• 关键词: Adverse effects; Animal Disease Models; Animal Model; Animals; Anti-Bacterial Agents; Antibiotic Therapy; Antibiotics; Aqueous Humor; Bandage; Basic Science; Biological; Chemical Engineering; Clinical; Competence; Contact Lenses; Cornea; Development; Devices; Disease; Doctor of Philosophy; Drops; Drug Combinations; Drug Delivery Systems; Drug Evaluation; Drug usage; Ear; Education; Evaluation; Eye; Eye diseases; Eyedrops; Fellowship; Film; Fostering; Glaucoma; Goals; Hypersensitivity; In Vitro; Institutes; Instruction; Keratitis; Kinetics; Massachusetts; Medical; Mentors; Microbiology; Ophthalmologic Surgical Procedures; Ophthalmology; Oryctolagus cuniculus; Patients; Pharmaceutical Preparations; Physiological; Polymers; Process; Research; Research Personnel; Research Project Grants; Residencies; Safety; Scientist; Self-Administered; Solutions; Staging; System; Techniques; Technology; Time; Tissue Engineering; Training; Training and Education; Universities; Work; absorption; biomaterial compatibility; career development; compliance behavior; controlled release; design; drug modification; in vivo; interest; member; next generation; programs; research study; skills; treatment effect

DESCRIPTION (provided by applicant): After completing my ophthalmology residency, I began a unique 2 year cornea fellowship at Massachusetts Eye & Ear Infirmary (MEEI). During the first year, I worked nearly exclusively on basic science research at Massachusetts Institute of Technology (MIT) in the Langer Lab, mentored by Daniel Kohane, MD, PhD and Claes Dohlman, MD, PhD. Along with cornea tissue engineering projects, we developed a drug-eluting contact lens. My principal clinical interest is in the treatment of cornea diseases. For most patients there is no alternative to topical solutions (drops) for medications such as antibiotics used after eye surgery. In addition, bandage contact lenses are often used in conjunction with antibiotics. This research will endeavor to create a new mode of ocular drug delivery: drug-eluting contact lenses. The benchtop research will continue with experiments in design modification and drug release studies before progressing to animal studies. The in vivo research follows a natural progression from studying the drug-eluting contact lens's effect under normal, physiologic conditions to its use as a treatment of disease (bacterial keratitis and glaucoma). This mentored research project in chemical engineering, microbiology, and ocular drug delivery, in conjunction with the appropriate coursework, aims to develop competence in biotechnological approaches to medical problems and ocular drug delivery. I will continue the research under my current mentor Daniel Kohane, an expert in polymer drug delivery, and James Chodosh, an expert in animal disease models. MEEI is a leader in ophthalmic research. MIT's Langer lab offers a world-class education in polymer technology. The research will be conducted with the support of a team of scientists and clinician-scientists who have mentored over a 100 private investigators in university settings. The personal relationship that I already have with the team members will be enriched by their expertise in their respective fields. They will help me to accomplish the research aims and mentor my career development. Thus, this program will foster the abilities and approach necessary to train me to become an independent investigator and possibly a leader in the next generation of clinician-scientists. RELEVANCE (See instructions): Drug eluting contact lenses would provide an alternative to eye drops, which are inefficient delivery system that can be difficult to self-administer, contain allergy-inducing preservatives, have a limited contact time with the eye, and cannot be used for many medications. More importantly, they would offer the possibility of treating eye diseases with a host of medications that cannot currently be delivered in a drop form.

描述（由申请人提供）：完成我的眼科住院医师后，我在马萨诸塞州Eye＆Ear医院（MEEI）开始了独特的2年角膜研究金。在第一年，我几乎在马萨诸塞州理工学院（MIT）的Langer Lab的基础科学研究中工作，由医学博士Daniel Kohane博士和Claes Dohlman，医学博士指导。除了角膜组织工程项目外，我们开发了一种洗脱药物的隐形眼镜。我的主要临床兴趣是治疗角膜疾病。对于大多数患者而言，无需替代局部溶液（滴），例如眼科手术后使用的抗生素。此外，绷带隐形眼镜通常与抗生素结合使用。这项研究将努力创造一种新的眼药递送方式：洗脱吸毒的隐形眼镜。台式研究将继续进行设计修饰和药物释放研究的实验，然后再进行动物研究。体内研究是在正常生理条件下研究药物洗脱隐形眼镜的作用到其用作疾病治疗（细菌性角膜炎和青光眼）的自然发展。该化学工程，微生物学和眼药输送的指导研究项目与适当的课程结合使用，旨在发展生物技术方法的能力，以解决医疗问题和眼药的能力。我将继续根据我目前的导师Daniel Kohane（聚合物药物输送专家）以及动物疾病模型专家James Chodosh继续进行研究。 Meei是眼科研究的领导者。 MIT的Langer Lab提供了世界一流的聚合物技术教育。这项研究将在科学家和临床医生团队的支持下进行，他们在大学环境中指导了100多名私人调查员。我已经与团队成员之间的个人关系将被各自领域的专业知识所丰富。他们将帮助我完成研究目标，并指导我的职业发展。因此，该计划将促进培训我成为独立研究者的能力和方法，并可能是下一代临床医生的领导者。相关性（请参阅说明）：洗脱的隐形眼镜将为眼滴提供一种替代方案，这些掉效率降低了，这可能难以自我管理，含有过敏的防腐剂，与眼睛的接触时间有限，并且不能用于许多药物。更重要的是，他们将提供可能通过目前无法以滴剂形式递送的大量药物治疗眼病的可能性。